Patrick Campbell

Professor Bertram Pitt discusses the results of FIGARO-DKD, what they add when combined with FIDELIO-DKD, and future research priorities moving forward in a Q&A with Practical Cardiology.

Despite increasing detection of atrial fibrillation and rates of anticoagulation, continuous electrocardiographic monitoring with an implantable loop recorder did not significantly reduce risk of stroke in the LOOP study.

An ESC Congress 2021 analysis suggests icosapent ethyl was associated with a 35% reduction in total primary end point events among patients with a history of myocardial infarction prior to enrollment in the REDUCE-IT trial.

ENVISAGE-TAVI AF is the first trial to compare edoxaban against standard of care in patients who have atrial fibrillation and have undergone successful TAVR.

FIGARO-DKD concluded use of finerenone was associated with a 13% reduction in the primary outcome, which investigators purport demonstrates the benefit of finerenone use in a population with milder chronic kidney disease than those included in FIDELIO-DKD.

Results of MASTER DAPT demonstrate an abbreviated period of DAPT rather than a standard approach preserves ischemic benefits and reduces bleeding risk in patients at a high bleeding risk following stent implantation.

A randomized trial presented at ESC Congress 2021, results of SMART-MI demonstrate use of ICMs could help improve detection of arrhythmia and improve outcomes in a patient population that would normally not be eligible for ICM implantation.

In an interview with Practical Cardiology, Javed Butler, MD, offers his perspective on the results of EMPEROR-Preserved and reflects on their rapid ascent into the cardiometabolic spotlight, evidenced by headlining trials at ESC Congress for the past 3 years.

Results of EMPEROR-Preserved demonstrate use of empagliflozin was associated with a 21% reduction in the composite end point of hospitalization for heart failure and cardiovascular death, with this effect mainly driven by a reduction in hospitalization for heart failure.

A pilot study found use of drones to deliver AEDs to patients with out-of-hospital cardiac arrest could improve response times compared to traditional emergency services.

An analysis of adherence to guideline-directed management at 1-year after ACS provides data suggesting optimal adherence could prolong event-free life expectancy by a median of 7.5 years.

Hailed by investigators as the largest and longest study of its kind, new research is providing clinicians with an overview of the potential for weight change and obesity among patients receiving gender-affirming hormone therapy.

A study presented at ESC 2021 details a significant rise in rates of cardiac arrests with a secondary diagnosis of opioid use in the United States from 2012-2018.

With approval awarded to Ascendis Pharma on August 25, lonapegsomatropin-tcgd (SKYTROFA) becomes the first once-weekly injection approved by the FDA to deliver somatropin by sustained release over a 1-week period.

The US Preventive Services Task Force has issued a B-graded recommendation statement lowering their recommended age for screening for type 2 diabetes from 40 to 35 years.

Data from the SEARCH for Diabetes in Youth Study suggests the prevalence of type 1 diabetes among youths have increased by nearly 50% from 2001-2017 and prevalence of type 2 diabetes increased by more than 95% during the same period.

Announced on August 24, rivaroxaban (Xarelto) has received its ninth indication from the US FDA. This time, the FDA has approved a label expansion to include patients with symptomatic peripheral artery disease who have undergone lower extremity revascularization.

With approval of the Evolut FX TAVR System announced on August 24, the Evolut TAVR Platform is now indicated for symptomatic severe aortic stenosis across all patient risk categories.

A new meta-analysis by investigators from Johns Hopkins details the prevalence of UACR testing in patient populations at increased risk of albuminuria, suggesting less than 40% of patients with diabetes underwent UACR testing and this figure dropped to less than 5% among patients with hypertension.

A review article details the prevalence and impact of sleep disorders in patients with type 2 diabetes as well as providing an overview current treatment options and research needs.

The approval of empagliflozin for reducing risk of CV death and hospitalization for heart failure in patients with HFrEF comes less than a year after results of EMPEROR-Reduced were presented at ESC 2020.

An analysis of registry data from more than 2.4 million births in Denmark suggests those born to mothers with diabetes were 39% more likely to experience high refractive error before turning 25 years old.

The latest scientific statement from the American Heart Association seeks to outline the cardiovascular risks associated with OSA or sleep-disordered breathing in children and adolescents while also providing insight into symptoms and risk factors for developing OSA or sleep-disordered breathing.

A recent analysis of health care spending data suggests nearly 1-in-6 heart failure patients forgo or delay care, while also suggesting delaying care ultimately increased healthcare spending by more than $8,000.

A recent study published in JAMA details increasing rates of gestational diabetes among first-time mothers in the US from 2011-2019, with rates increasing across all racial/ethnic subgroups examined in the 12 million person analysis.

A substudy of a prospective observational study performed at a hospital in Italy details potential associations of vitamin D levels with BMI and blood glucose and severity of COVID-19.

Eli Lilly and Company announced the FDA has expanded the label of insulin lispro-aabc injection (Lyumjev) to allow for administration via insulin pumps.

Using propensity score-matching, a new study is providing insight into the risk reduction and bleeding risk associated with various DOACs versus warfarin and one another in patients with nonvalvular atrial fibrillation and an increased gastrointestinal bleeding risk.

An analysis of data from a national health database in South Korea suggests increased BMI variability was linked to a 66% greater risk of mortality and a 19% greater risk of heart attack and stroke in patients with chronic kidney disease.

An analysis of more than 50,000 patients with chronic kidney disease indicates increased BMI variability was tied to increased risk of mortality, need for kidney replacement therapy, and cardiovascular disease events.